# Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder

> **NCT01168895** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 12 (actual)

## Conditions studied

- Infection
- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Cipro Inhale (Ciprofloxacin, BAYQ3939)
- **DRUG:** Cipro Inhale (Ciprofloxacin, BAYQ3939)

## Key facts

- **NCT ID:** NCT01168895
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01168895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01168895, "Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01168895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*